Patents Examined by Vasu S. Jagannathan
  • Patent number: 5744442
    Abstract: A method for decreasing metalloproteinase activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. Also, a method for increasing TIMP activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. In addition a method for inhibiting or treating progression of a tumor in a patient that comprises the step of administering to said patient a therapeutic composition comprising oncostatin-M, or a biologically active fragment, mutant, analog, or fusion construct thereof, said method being effective to inhibit invasion by a tumor cell through an extracellular space, extracellular matrix, basement membrane, interstitial tissue or connective tissue.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: April 28, 1998
    Assignees: Bristol Meyers Squibb Company, McMaster University
    Inventors: Carl D. Richards, Mohammed Shoyab, Jack Gauldie, Thomas Joseph Brown
  • Patent number: 5736363
    Abstract: Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino add residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: April 7, 1998
    Assignee: British Bio-technology Limited
    Inventors: Richard Mark Edwards, Lindsay Bawden
  • Patent number: 5736339
    Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K* is a modified lysyl residue of the formulaR.sup.1.sub.2 N(CH.sub.2).sub.4 CHNHCO--wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C) or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sub.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 7, 1998
    Assignee: COR Therapeutics, Inc.
    Inventors: Robert M. Scarborough, David Lawrence Wolf, Israel F. Charo
  • Patent number: 5733720
    Abstract: A diagnostic assay for detecting the presence of an infectious herpesvirus in a specimen and a genetically engineered cell line for use in such assay are disclosed. The cell line used in the assay expresses a reporter gene only if infectious herpesvirus is present in the specimen. The assay involves inoculating a DNA-transfected cell line with a specimen suspected of containing a herpesvirus, allowing a sufficient period of time for the herpesvirus infectious cycle to proceed, and detecting and quantifying the number of herpesvirus-infected cells to determine the number of infectious herpesvirus virions in the specimen. The cell line is a DNA-transfected cell line susceptible to infection by a herpesvirus which is stably transformed with a chimeric gene comprising a herpesvirus inducible promoter and a gene coding for an enzyme, the expression of the enzyme being dependent upon and quantitatively proportional to the presence of herpesvirus. A kit for such assay is also provided.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: March 31, 1998
    Assignee: Washington University
    Inventor: Paul D. Olivo
  • Patent number: 5731415
    Abstract: Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: March 24, 1998
    Assignee: XOMA Corporation
    Inventors: Helene Gazzano-Santoro, Georgia Theofan, Patrick W. Trown
  • Patent number: 5731419
    Abstract: The present invention relates to three novel genes which have been isolated from cold-tolerant wheat species and which are induced by low temperature. The first gene, Wcs19, is preferentially expressed in green leaf tissues of tolerant gramineae species and requires both light and low temperature for maximal induction. The second gene, Wcs120, is induced only by low temperature. Different from the protein encoded by Wcs19, the protein encoded by Wcs120 contains two repeated domains that are highly conserved among RAB (rice abscisic acid-induced) and dehydrin families and appears to be light-independent. The Wcs120 protein does not however contain a serine-rich sequence present in RAB and dehydrin families. Finally, the present invention also relates to a third gene, Wcor410, also induced by low temperature as well as water stress and, to a lesser extend, by ABA. Its expression is light-independent. The protein encoded by this gene contains a serine-rich stretch as found in several drought induced proteins.
    Type: Grant
    Filed: August 16, 1993
    Date of Patent: March 24, 1998
    Assignee: Universite du Quebec a Montreal
    Inventors: Fathey Sarhan, Mario Houde, Jean-Francois Laliberte
  • Patent number: 5728815
    Abstract: The role for a substantially purified human growth factor preparation is shown to contain a distinct polypeptide with apparent M.sub.r on SDS/PAGE of about 220 kD, and to be distinct from bFGF, with a most active fraction at about 220 kD. A human growth factor polypeptide of 157 kD was identified, in human bone marrow aspirates and from bone stromal cells, by immunoblotting with the mAb MS 329, and by affinity isolation using a MS 329 antibody column. A PSA stimulating autocrine factor, PSAF, that is precipitable in ammonium sulfate at between 60-80% saturation is able to induce PSA expression and secretion, and serves as an indicator of androgen independent prostate cell growth.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: March 17, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventors: Leland W. K. Chung, James Chan, Christopher Logothetis, Jer-Tsong Hsieh
  • Patent number: 5723115
    Abstract: Epidermal growth factor (EGF), which can act as a potent inhibitor of adipocyte differentiation in vitro, affects adipose tissue differentiation in vivo and can suppress obesity. Methods are provided for inhibiting the differentiation of adipocyte precursor cells, and for treating or preventing obesity, which comprise administering an effective amount of a composition capable of binding to and activating the EGF receptor, preferably epidermal EGF or a functional derivative thereof, TGF.alpha., an antibody specific for the EGF receptor or an anti-idiotypic antibody specific for an idiotope on an antibody specific for EGF. Also provided is a method for determining the susceptibility of a subject to obesity or determining the presence of obesity associated with an abnormality in EGF or EGF receptor, which comprises measuring EGF in a body fluid or the amount or activity of EGF receptor protein or mRNA in adipocyte precursors.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: March 3, 1998
    Assignee: W. Alton Jones Cell Science Center, Inc.
    Inventor: Ginette Serrero
  • Patent number: 5723309
    Abstract: Soluble, single chain T cell receptors, nucleic acid sequences, particularly DNA sequences, encoding the soluble, single chain T cell receptor, expression vectors containing the DNA sequences, and host cells containing the expression vectors.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: March 3, 1998
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Immunotech
    Inventor: Marc Bonneville
  • Patent number: 5719044
    Abstract: A cellulose binding domain (CBD) having a high affinity for crystalline cellulose and chitin is disclosed, along with methods for the molecular cloning and recombinant production thereof. Fusion products comprising the CBD and a second protein are likewise described. A wide range of applications are contemplated for both the CBD and the fusion products, including drug delivery, affinity separations, and diagnostic techniques.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 17, 1998
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Regents of the University of California
    Inventors: Oded Shoseyov, Itai Shpiegl, Marc A. Goldstein, Roy H. Doi
  • Patent number: 5716810
    Abstract: DNA encoding the prepro inhibin .alpha. and .beta. chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibin .alpha. or .beta. chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Anthony J. Mason, Peter H. Seeburg
  • Patent number: 5714144
    Abstract: Novel human tissue-type plasminogen activator variant that a) retains substantially full biological activity b) has a modified carbohydrate structure and c) has an altered in vivo half-life. Means for preparation of the variants and results of assays measuring function of the activators are also disclosed.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: February 3, 1998
    Assignee: Genentech, Inc.
    Inventors: Adair J. Hotchkiss, John V. O'Connor, Michael W. Spellman
  • Patent number: 5712144
    Abstract: Full-length and deletion subclones of cDNAs for Factor C of Carcinoscorpius rotundicauda are provided. These cDNAs have been cloned into 22 and pGEM 11Zf(+). Further manipulations of the 5' and 3' ends of these cDNAs have been carried out, and these cDNAs have been further subcloned into other expression vectors such as pGEMEX-1, pET 3b, and the yeast shuttle vectors YEpsec 1 and pEMBLyex 4, and pPIC 9 and pHIL D2. Also provided are host cells transformed with expression vectors containing DNA molecules encoding proteins having Factor C-like enzymatic activity, methods of producing such proteins, methods for purifying Factor C zymogens, and methods for protecting Factor C zymogens from autoactivation by Gram negative bacterial endotoxin while the proenzyme is being purified and/or processed from amoebocyte lysates or from recombinant clones, or during storage or subsequent handling. This protection is afforded by the addition of 5-30% Me.sub.2 SO, which reversibly inhibits the Factor C zymogen.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 27, 1998
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Patent number: 5712314
    Abstract: A resin composition useful in well completion and remedial methods having improved flexibility upon setting or curing is disclosed. The resin composition includes a polymerizable resin, an oil soluble acid catalyst capable of causing polymerization of the resin at formation temperatures, and 10 to 70% by volume rubber. The rubber may be in the form of ground rubber or an aqueous dispersion or emulsion. Also disclosed are methods for the use of the resin composition in well completion and remediation.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: January 27, 1998
    Assignee: Texaco Inc.
    Inventors: Billy Wayne Surles, Philip Daniel Fader
  • Patent number: 5708136
    Abstract: A human gene has been discovered which is genetically altered in human tumor cells. The genetic alteration is gene amplification and leads to a corresponding increase in gene products. Detecting that the gene, designated hMDM2, has become amplified or detecting increased expression of gene products is diagnostic of tumorigenesis. Human MDM2 protein binds to human p53 and allows the cell to escape from p53-regulated growth.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: January 13, 1998
    Assignee: The Johns Hopkins University
    Inventors: Marilee Burrell, David E. Hill, Kenneth W. Kinzler, Bert Vogelstein
  • Patent number: 5708134
    Abstract: This invention is directed to isolated human AlaGlu-IGF-1, a novel compound which exerts IGF-1 activity and is a valuable precursor in the preparation of IGF-1 itself.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: January 13, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Lars Skriver, Kim Ry butted.s, Henrik Dalb.o
  • Patent number: 5708148
    Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: January 13, 1998
    Assignee: CIBA GEIGY Corporation
    Inventors: Albert Schmitz, Walter Marki
  • Patent number: 5705609
    Abstract: The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein. The protein is characterized by a leucine-rich repeat of about 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, and more specifically to active fragments of decorin or its functional equivalents to bind TGF.beta.. The invention also provides a novel cell regulatory factor designated MRF. Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins which bind and affect the activity of cell regulatory factors.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: January 6, 1998
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Michael D. Pierschbacher, Jose Cardenas, William Craig, Daniel G. Mullen
  • Patent number: 5705477
    Abstract: A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: January 6, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael B. Sporn, Anita B. Roberts
  • Patent number: 5703134
    Abstract: New copolymers of recycled polyesters having improved properties are disclosed. The copolyesters are produced by a reaction of recycled polyalkylene terephthalate and a dicarboxylate moiety.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: December 30, 1997
    Assignee: Monsanto Company
    Inventors: Jawed Asrar, A. Hameed Bhombal